# Who are Biogen Inc.'s customers? Who does Biogen Inc. earn revenue from?
Canonical: https://valuechain.wiki/biogen · Facet: customers · Updated: 2026-09-23T09:44:39.939106+00:00 · Source: ValueChain.wiki (cited money-flow graph)

**Citable summary**: Biogen Inc.'s confirmed revenue counterparties include Eisai, Cencora, Inc., McKesson Corporation plus 1 undisclosed/aggregate relationship. Per the valuechain.wiki graph: 4 revenue edges, backed by 2 dated sources, 2 of them primary filings (as of 2026-09-23).

### 에자이 (high)  → /eisai.md
- metric: Amount $178M · FY2025 · Alzheimer's collaboration revenue recognized from the Eisai LEQEMBI collaboration
- note: Biogen co-commercializes LEQEMBI with Eisai and recognizes 50% of collaboration economics after net product revenue and cost of sales. FY2025 Alzheimer's collaboration revenue was $177.7 million.
- [confirms] SEC EDGAR (EN, filing, published 2026-02-06) https://www.sec.gov/Archives/edgar/data/875045/000087504526000013/biib-20251231.htm: "For the year ended December 31, 2025, we recognized Alzheimer's collaboration revenue of approximately $177.7 million."

### 센코라 (high)  → /cencora.md
- metric: Revenue share 33 PERCENT · FY2014 · AmerisourceBergen share of Biogen gross product revenue
- note: AmerisourceBergen, now Cencora, was a major U.S. wholesale distributor for Biogen. In FY2014 it exceeded 10% of total revenue and represented 33% of gross product revenue.
- [confirms] SEC EDGAR (EN, filing, published 2015-02-04) https://www.sec.gov/Archives/edgar/data/875045/000087504515000005/biib-20141231x10k.htm: "We recorded revenue from two wholesalers accounting for 33% and 27% of gross product revenues in 2014, respectively."

### 맥케슨 (high)  → /mckesson.md
- metric: Revenue share 27 PERCENT · FY2014 · McKesson share of Biogen gross product revenue
- note: McKesson was a major U.S. wholesale distributor for Biogen. In FY2014 it exceeded 10% of total revenue and represented 27% of gross product revenue.
- [confirms] SEC EDGAR (EN, filing, published 2015-02-04) https://www.sec.gov/Archives/edgar/data/875045/000087504515000005/biib-20141231x10k.htm: "AmerisourceBergen and McKesson each accounted for more than 10% of our total revenues in 2014."

### Genentech, Inc. (Roche Group) (high)
- metric: Revenue share 18.8 PERCENT · FY2025 · Share of Biogen total revenue derived from Genentech collaboration arrangements
- note: Genentech and the Roche Group pay Biogen profit shares and royalties on anti-CD20 therapies including RITUXAN, GAZYVA and OCREVUS. These arrangements generated 18.8% of Biogen's FY2025 revenue.
- [confirms] SEC EDGAR (EN, filing, published 2026-02-06) https://www.sec.gov/Archives/edgar/data/875045/000087504526000013/biib-20251231.htm: "Approximately 18.8% of our total revenue in 2025 was derived from our collaboration arrangements with Genentech."

Reverse side: https://valuechain.wiki/biogen/suppliers.md · Ripple: https://valuechain.wiki/biogen/ripple.md

---
Full node: https://valuechain.wiki/biogen.md · JSON: https://valuechain.wiki/biogen.json